Sign in

You're signed outSign in or to get full access.

SH

STREAMLINE HEALTH SOLUTIONS INC. (STRM)·Q4 2025 Earnings Summary

Executive Summary

  • Q4 (quarter ended Jan 31, 2025): Revenue was $4.70M, up sequentially from $4.42M in Q3 but down YoY (Q4 FY2023: $5.4M). Net loss improved sequentially to ($2.1M). SaaS revenue was $3.1M (66% mix) as non‑renewals and lower legacy revenue continued to weigh, partially offset by new bookings and go‑lives .
  • Management launched denial-prevention functionality within eValuator and reiterated an adjusted EBITDA positive run-rate in the first half of FY2025, signaling a path to profitability despite revenue headwinds .
  • Booked SaaS ACV was $14.0M as of Jan 31, 2025, and $14.6M as of Apr 30, 2025 (of which $13.1M implemented), reflecting modest net bookings progress after churn earlier in the year; management highlighted Oracle channel traction (CommunityWorks) and faster implementations as near-term catalysts .
  • Consensus estimates from S&P Global were unavailable for Q4, so beat/miss vs Street cannot be assessed; investors should focus on sequential trends, ACV/implementation progress, and the new denial-prevention launch as key stock catalysts. Values retrieved from S&P Global were unavailable.

What Went Well and What Went Wrong

  • What Went Well

    • Denial-prevention launched in eValuator; CEO expects it to expand inpatient financial impact by >15% and potentially double outpatient impact based on back-testing and payer behavior modeling .
    • Oracle channel momentum: $350K of new RevID bookings via Oracle, plus a new CommunityWorks client; management expects continued wins from this channel .
    • Implementation velocity: Recent eValuator go‑live completed in 42 days; overall timelines materially improved vs prior years; run-rate adjusted EBITDA profitability reiterated for 1H FY2025 .

  • What Went Wrong

    • Revenue still pressured by SaaS non‑renewals and lower legacy Maintenance/Support and professional services; Q4 revenue fell YoY to $4.7M (from $5.4M) .
    • Q4 net loss widened YoY to ($2.1M) due to lower revenue and higher non‑cash interest expense (partly offset by lower opex) .
    • Liquidity/covenants: Cash was $2.2M at Jan 31; company amended covenants and drew an additional $1.0M on Mar 28, 2025—highlighting balance sheet constraints .

Financial Results

MetricQ2 FY2024 (ended Jul 31, 2024)Q3 FY2024 (ended Oct 31, 2024)Q4 FY2024 (ended Jan 31, 2025)
Total Revenue ($M)$4.48 $4.42 $4.70
SaaS Revenue ($M)$3.078 $2.933 $3.10
SaaS Mix (%)69% 66% 66%
Net Loss ($M)($2.803) ($2.476) ($2.1)
Adjusted EBITDA ($M)($0.302) ($0.326) $0.035

KPIs and Bookings/ACV

  • Booked SaaS ACV ($M): $13.6 (Jul 31, 2024) ; $14.1 (Oct 31, 2024) ; $14.0 (Jan 31, 2025) ; $14.6 (Apr 30, 2025, expected) .
  • Implemented ACV ($M): $10.7 (Jul 31, 2024) ; $12.0 (Oct 31, 2024) ; $13.1 (Apr 30, 2025, of $14.6 total) .
  • Cash & Equivalents ($M): $3.54 (Jul 31, 2024) ; $0.75 (Oct 31, 2024) ; $2.18 (Jan 31, 2025) .
  • Debt/Facilities: $1.0M revolver outstanding at Jan 31, 2025; additional $1.0M drawn Mar 28, 2025; covenant amendments executed .

Notes:

  • Results reflect continued impact from previously announced SaaS non‑renewals and reduced legacy revenue; sequential Q4 improvement reflects new bookings and go‑lives .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Adjusted EBITDA run-rate breakeven timingFY2025Second half FY2025 (updated at Q2 FY2024) First half FY2025 (accelerated at Q3; reiterated in Q4) Raised (sooner) at Q3; maintained in Q4
Bookings timing specificityOngoingNot provided due to unpredictability Not provided due to unpredictability Maintained

No revenue, margin, OpEx, OI&E, or tax guidance ranges were provided; management focused on adjusted EBITDA run-rate timing and refrained from bookings timing given variability .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q4)Trend
Path to profitabilityQ2: Breakeven pushed to 2H FY2025 due to non‑renewals; cost actions helping adjusted EBITDA . Q3: Accelerated to 1H FY2025 .Reiterated adjusted EBITDA positive run-rate in 1H FY2025 .Improving/maintained confidence
Denials prevention / product innovationQ3: Introduced quality module; expanding client relationships .Launched denial-prevention rules in eValuator; expected to lift impact (>15% inpatient; potentially double outpatient) .Strengthening product value proposition
Oracle channel / CommunityWorksQ2/Q3: Building channel; bookings variability .$350K RevID bookings via Oracle; new CommunityWorks client; more wins expected .Positive momentum
Implementation speedQ2/Q3: Working to improve timelines .eValuator go‑live in 42 days; RevID timelines improving using eValuator playbook .Accelerating
Revenue headwindsQ2/Q3: Non‑renewals pressured revenue and mix; legacy declines .Continued impact; Q4 YoY revenue down, SaaS mix stable at 66% .Lingering but stabilizing mix

Management Commentary

  • “As of January 31, 2025, our solutions are delivering an annualized financial impact of more than $210 million to our clients… Our new denial prevention functionality within eValuator… helps clients prevent denials in real time” .
  • “As of April 30, 2025, Booked SaaS ACV totaled $14.6 million, $13.1 million of which was implemented… We expect continued wins from [the Oracle] channel” .
  • “Our most recent eValuator go-live was completed 42 days after contract signature… we maintain our expectation related to achieving an EBITDA profitable run rate as we exit the second quarter of fiscal 2025” .

Q&A Highlights

  • Denials prevention readiness and value proposition: Management emphasized integrating payer-denial signals into pre-bill workflows to make claims “bulletproof,” with clients highly engaged and results now quantifiable for executive audiences .
  • Implementation timelines: Average durations have fallen materially (eValuator now ~2–3 months; recent 42-day example); RevID timelines are improving by adopting the eValuator playbook .
  • Bookings momentum: Leaning into client-led marketing (webinars, peer stories, Oracle conference) to drive top-of-funnel activity after salesforce changes; seeing increased engagement .

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 FY2024 (reported May 2025) was unavailable at the time of retrieval; as a result, we cannot assess revenue or EPS beats/misses for the quarter. Values retrieved from S&P Global were unavailable.

Additional Q4 Press Releases

  • Jan 15, 2025: New eValuator contract with Deaconess Health System (1,200 beds) to optimize pre-bill coding accuracy .
  • Jan 22, 2025: New RevID contract with a 120-bed Kentucky health system via Oracle CommunityWorks—fourth CommunityWorks client, reinforcing Oracle channel traction .

Key Takeaways for Investors

  • Sequential stabilization with improving profitability trajectory: Q4 revenue rose to $4.70M from $4.42M in Q3 and adjusted EBITDA ticked positive ($0.035M) as cost actions and implementation pace offset non‑renewal headwinds .
  • Product catalyst: Denials prevention within eValuator is a tangible differentiator with management expecting meaningful impact expansion; watch for adoption and upsell into installed base .
  • Channel and pipeline: Oracle CommunityWorks momentum (new client; $350K RevID bookings) and client-led marketing should support bookings; implemented ACV growth is the near-term driver of ARR and profitability .
  • Liquidity watch: Low cash and additional revolver draw plus covenant amendments suggest tight funding; execution toward EBITDA-positive run-rate in 1H FY2025 is critical to alleviate financing risk .
  • Estimate visibility gap: With Street consensus unavailable, trading may anchor to sequential trends (revenue, adjusted EBITDA) and qualitative catalysts (product launch, Oracle channel) until coverage improves. Values retrieved from S&P Global were unavailable.

Appendix: Prior Two Quarters (for trend)

MetricQ2 FY2024 (ended Jul 31, 2024)Q3 FY2024 (ended Oct 31, 2024)
Total Revenue ($M)$4.48 $4.42
SaaS Revenue ($M)$3.078 $2.933
Net Loss ($M)($2.803) ($2.476)
Adjusted EBITDA ($M)($0.302) ($0.326)
Booked SaaS ACV ($M)$13.6 (as of Jul 31) $14.1 (as of Oct 31)
Implemented ACV ($M)$10.7 (as of Jul 31) $12.0 (as of Oct 31)

Sources:

  • Q4/FY press release & 8‑K (May 1, 2025) .
  • Q4 earnings call (May 2, 2025) .
  • Q3 press release (Dec 16, 2024) .
  • Q2 press release (Sept 11, 2024) .